Detection of EPO gene doping in blood
- Publikationstyp:
- Zeitschriftenaufsatz
- Metadaten:
-
- Autoren
- Elmo WI Neuberger
- Magdalena Jurkiewicz
- Dirk A Moser
- Perikles Simon
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000311436000008&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1002/dta.1347
- eISSN
- 1942-7611
- Externe Identifier
- Clarivate Analytics Document Solution ID: 041XT
- PubMed Identifier: 22508654
- ISSN
- 1942-7603
- Ausgabe der Veröffentlichung
- 11
- Zeitschrift
- DRUG TESTING AND ANALYSIS
- Schlüsselwörter
- gene doping
- gene therapy
- detection
- EPO
- erythropoietin
- Paginierung
- 859 - 869
- Datum der Veröffentlichung
- 2012
- Status
- Published
- Titel
- Detection of EPO gene doping in blood
- Sub types
- Review
- Ausgabe der Zeitschrift
- 4
Datenquelle: Web of Science (Lite)
- Andere Metadatenquellen:
-
- Abstract
- <jats:p>Gene doping – or the abuse of gene therapy – will continue to threaten the sports world. History has shown that progress in medical research is likely to be abused in order to enhance human performance. In this review, we critically discuss the progress and the risks associated with the field of erythropoietin (EPO) gene therapy and its applicability to EPO gene doping. We present typical vector systems that are employed in <jats:italic>ex vivo</jats:italic> and <jats:italic>in vivo</jats:italic> gene therapy trials. Due to associated risks, gene doping is not a feasible alternative to conventional EPO or blood doping at this time. Nevertheless, it is well described that about half of the elite athlete population is in principle willing to risk its health to gain a competitive advantage. This includes the use of technologies that lack safety approval. Sophisticated detection approaches are a prerequisite for prevention of unapproved and uncontrolled use of gene therapy technology. In this review, we present current detection approaches for EPO gene doping, with a focus on blood‐based direct and indirect approaches. Gene doping is detectable in principle, and recent DNA‐based detection strategies enable long‐term detection of transgenic DNA (tDNA) following <jats:italic>in vivo</jats:italic> gene transfer. Copyright © 2012 John Wiley & Sons, Ltd.</jats:p>
- Autoren
- Elmo WI Neuberger
- Magdalena Jurkiewicz
- Dirk A Moser
- Perikles Simon
- DOI
- 10.1002/dta.1347
- eISSN
- 1942-7611
- ISSN
- 1942-7603
- Ausgabe der Veröffentlichung
- 11
- Zeitschrift
- Drug Testing and Analysis
- Sprache
- en
- Online publication date
- 2012
- Paginierung
- 859 - 869
- Datum der Veröffentlichung
- 2012
- Status
- Published
- Herausgeber
- Wiley
- Herausgeber URL
- http://dx.doi.org/10.1002/dta.1347
- Datum der Datenerfassung
- 2023
- Titel
- Detection of <i>EPO</i> gene doping in blood
- Ausgabe der Zeitschrift
- 4
Datenquelle: Crossref
- Abstract
- Gene doping--or the abuse of gene therapy--will continue to threaten the sports world. History has shown that progress in medical research is likely to be abused in order to enhance human performance. In this review, we critically discuss the progress and the risks associated with the field of erythropoietin (EPO) gene therapy and its applicability to EPO gene doping. We present typical vector systems that are employed in ex vivo and in vivo gene therapy trials. Due to associated risks, gene doping is not a feasible alternative to conventional EPO or blood doping at this time. Nevertheless, it is well described that about half of the elite athlete population is in principle willing to risk its health to gain a competitive advantage. This includes the use of technologies that lack safety approval. Sophisticated detection approaches are a prerequisite for prevention of unapproved and uncontrolled use of gene therapy technology. In this review, we present current detection approaches for EPO gene doping, with a focus on blood-based direct and indirect approaches. Gene doping is detectable in principle, and recent DNA-based detection strategies enable long-term detection of transgenic DNA (tDNA) following in vivo gene transfer.
- Addresses
- Department of Sports Medicine, Rehabilitation and Disease Prevention, Johannes Gutenberg University Mainz, Mainz, Germany.
- Autoren
- Elmo WI Neuberger
- Magdalena Jurkiewicz
- Dirk A Moser
- Perikles Simon
- DOI
- 10.1002/dta.1347
- eISSN
- 1942-7611
- Externe Identifier
- PubMed Identifier: 22508654
- Funding acknowledgements
- NIGMS NIH HHS: T32 GM008444
- Open access
- false
- ISSN
- 1942-7603
- Ausgabe der Veröffentlichung
- 11
- Zeitschrift
- Drug testing and analysis
- Schlüsselwörter
- Animals
- Humans
- Erythropoietin
- DNA
- Gene Transfer Techniques
- Substance Abuse Detection
- Transgenes
- Doping in Sports
- Transcriptome
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2012
- Paginierung
- 859 - 869
- Datum der Veröffentlichung
- 2012
- Status
- Published
- Datum der Datenerfassung
- 2012
- Titel
- Detection of EPO gene doping in blood.
- Sub types
- Research Support, Non-U.S. Gov't
- Review
- Journal Article
- Ausgabe der Zeitschrift
- 4
Datenquelle: Europe PubMed Central
- Abstract
- Gene doping--or the abuse of gene therapy--will continue to threaten the sports world. History has shown that progress in medical research is likely to be abused in order to enhance human performance. In this review, we critically discuss the progress and the risks associated with the field of erythropoietin (EPO) gene therapy and its applicability to EPO gene doping. We present typical vector systems that are employed in ex vivo and in vivo gene therapy trials. Due to associated risks, gene doping is not a feasible alternative to conventional EPO or blood doping at this time. Nevertheless, it is well described that about half of the elite athlete population is in principle willing to risk its health to gain a competitive advantage. This includes the use of technologies that lack safety approval. Sophisticated detection approaches are a prerequisite for prevention of unapproved and uncontrolled use of gene therapy technology. In this review, we present current detection approaches for EPO gene doping, with a focus on blood-based direct and indirect approaches. Gene doping is detectable in principle, and recent DNA-based detection strategies enable long-term detection of transgenic DNA (tDNA) following in vivo gene transfer.
- Date of acceptance
- 2012
- Autoren
- Elmo WI Neuberger
- Magdalena Jurkiewicz
- Dirk A Moser
- Perikles Simon
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/22508654
- DOI
- 10.1002/dta.1347
- eISSN
- 1942-7611
- Funding acknowledgements
- NIGMS NIH HHS: T32 GM008444
- Ausgabe der Veröffentlichung
- 11
- Zeitschrift
- Drug Test Anal
- Schlüsselwörter
- Animals
- DNA
- Doping in Sports
- Erythropoietin
- Gene Transfer Techniques
- Humans
- Substance Abuse Detection
- Transcriptome
- Transgenes
- Sprache
- eng
- Country
- England
- Paginierung
- 859 - 869
- Datum der Veröffentlichung
- 2012
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2013
- Titel
- Detection of EPO gene doping in blood.
- Sub types
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
- Ausgabe der Zeitschrift
- 4
Datenquelle: PubMed
- Beziehungen:
- Eigentum von